Abstract |
The optimal timing for recombinant human (rh) G-CSF administration after chemotherapy for PBSC mobilization has not yet been determined. In this study, we compared two different time schedules of rhG-CSF; 4th (early) vs 7th day (late), in 48 consecutive patients with multiple myeloma and lymphoma undergoing PBSC mobilization with CE (CY 4 g/m(2) on day 1 and etoposide 200 mg/m(2) on days 1-3). The rhG-CSF dose was 10 microg/kg/day for all patients. Both groups were comparable in terms of sex, age and number of previously given different chemotherapy regimens. Duration of neutropenia, CD34(+) cell count on the first day of apheresis and numbers of aphereses were not statistically different between the two arms. However, the number of doses of rhG-CSF up to the first cycle of apheresis procedures was significantly lower in the late group than in the early group (P=0.005). The median number of total CD34(+) cells collected was 10.54 x 10(6)/kg (range 0.11-37.27) in the early group and 10.81 x 10(6)/kg (range 0.17-49.83) in the late group of rhG-CSF (P=0.781). We conclude that PBSC mobilization after late use of rhG-CSF is an effective approach and therefore, in routine clinical practice, late rhG-CSF may be used for PBSC collections after chemotherapy-based mobilization regimens in this cost-conscious era.
|
Authors | T Ozcelik, P Topcuoglu, M Beksac, M Ozcan, M Arat, Z Biyikli, S M Bakanay, O Ilhan, G Gurman, O Arslan, T Demirer |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 44
Issue 12
Pg. 779-83
(Dec 2009)
ISSN: 1476-5365 [Electronic] England |
PMID | 19597420
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Antigens, CD34
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
|
Topics |
- Adult
- Antigens, CD34
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage)
- Female
- Granulocyte Colony-Stimulating Factor
(administration & dosage)
- Hematopoietic Stem Cell Mobilization
(methods)
- Humans
- Leukapheresis
(methods)
- Lymphoma, Non-Hodgkin
(blood, therapy)
- Male
- Middle Aged
- Multiple Myeloma
(blood, therapy)
- Neutropenia
(blood, chemically induced)
- Peripheral Blood Stem Cell Transplantation
- Recombinant Proteins
- Time Factors
- Transplantation, Autologous
|